Why do generics suffer more than originator products from the lack of a European single market in pharmaceuticals?
Since 1998 EU law has obliged generics to have the same uses and information in all EU countries. However, the originator brands registered before 1998 are allowed to maintain different uses and information from country to country. This makes it very difficult to register and market generics in the various Member States.
